Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 21.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,151 shares of the medical research company's stock after selling 17,256 shares during the period. Kennedy Capital Management LLC owned about 0.12% of Charles River Laboratories International worth $11,658,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in CRL. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $48,000. Tortoise Investment Management LLC raised its stake in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after buying an additional 115 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International in the third quarter worth $59,000. 98.91% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Finally, Barclays decreased their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Stock Down 0.5 %

Shares of NYSE CRL traded down $0.58 during midday trading on Tuesday, hitting $106.02. The company's stock had a trading volume of 2,845,037 shares, compared to its average volume of 878,892. The firm has a market capitalization of $5.21 billion, a price-to-earnings ratio of 706.79, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business's fifty day simple moving average is $155.52 and its two-hundred day simple moving average is $176.21.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.46 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).